Jason Rush

Keywords binder first signalosome innate immunity coiled coil drug discovery Crohn's disease fungal immunity small molecule inhibitor immune-mediated disease Get full text access Log in, subscribe or purchase for full access. References 1. Okada, Y. ∙ Wu, D. ∙ Trynka, G. ... Genetics of rheumatoid arthritis contributes to biology and drug discovery Nature. 2014; 506:376-381 2. Kurki, M.I. ∙ Karjalainen, J. ∙ Palta, P. ... FinnGen provides genetic insights from a well-phenotyped isolated population Nature.

The release of the FDA’s guidance related to diversity in clinical trials details what trials need DAPs, what should be included, and how to submit them. Will this be the turning point that shifts the conversation surrounding diversity from marketing rhetoric to actual implementations? Join Clinical Leader Live on September 5th for a digital discussion on what is working now to improve the representation of age, sex, racial, and ethnic demographic characteristics in trials today.

Abstract Protein phosphatase, Mg2+/Mn2+ dependent 1D (PPM1D), is a serine/threonine phosphatase that is recurrently activated in cancer, regulates the DNA damage response (DDR), and suppresses the activation of p53. Consistent with its oncogenic properties, genetic loss or pharmacologic inhibition of PPM1D impairs tumor growth and sensitizes cancer cells to cytotoxic therapies in a wide range of preclinical models.